ORENCIA approved for the treatment of Psoriatic Arthritis
by News Desk from Outbreak News Today on (#2W9HM)
U.S. Food and Drug Administration (FDA) last week approved the Psoriatic Arthritis (PsA) treatment, ORENCIA (abatacept) by Bristol-Myers Squibb Company. ORENCIA is approved and available in both intravenous and subcutaneous (SC) injection formulations for the treatment of adults with active PsA. This approval marks the third autoimmune disease indication for ORENCIA. "This approval underscores the efficacy of ORENCIA in adult patients ["]
The post ORENCIA approved for the treatment of Psoriatic Arthritis appeared first on Outbreak News Today.